vs
波士顿科学（BSX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是Revvity的6.7倍（$5.2B vs $772.1M），波士顿科学净利率更高（25.7% vs 12.7%，领先13.0%），波士顿科学同比增速更快（11.6% vs 5.9%），过去两年波士顿科学的营收复合增速更高（12.4% vs 9.0%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BSX vs RVTY — 直观对比
营收规模更大
BSX
是对方的6.7倍
$772.1M
营收增速更快
BSX
高出5.7%
5.9%
净利率更高
BSX
高出13.0%
12.7%
两年增速更快
BSX
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $772.1M |
| 净利润 | $1.3B | $98.4M |
| 毛利率 | 69.5% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 25.7% | 12.7% |
| 营收同比 | 11.6% | 5.9% |
| 净利润同比 | 99.0% | 3.9% |
| 每股收益（稀释后） | $0.90 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXRVTY
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $772.1M | ||
| Q3 25 | $5.1B | $698.9M | ||
| Q2 25 | $5.1B | $720.3M | ||
| Q1 25 | $4.7B | $664.8M | ||
| Q4 24 | $4.6B | $729.4M | ||
| Q3 24 | $4.2B | $684.0M | ||
| Q2 24 | $4.1B | $691.7M |
净利润BSXRVTY
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $98.4M | ||
| Q3 25 | $755.0M | $46.7M | ||
| Q2 25 | $795.0M | $53.9M | ||
| Q1 25 | $672.0M | $42.2M | ||
| Q4 24 | $563.0M | $94.6M | ||
| Q3 24 | $468.0M | $94.4M | ||
| Q2 24 | $322.0M | $55.4M |
毛利率BSXRVTY
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | — | ||
| Q3 25 | 69.9% | 53.6% | ||
| Q2 25 | 67.7% | 54.5% | ||
| Q1 25 | 68.8% | 56.5% | ||
| Q4 24 | 67.8% | — | ||
| Q3 24 | 68.8% | 56.3% | ||
| Q2 24 | 69.2% | 55.7% |
营业利润率BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 14.5% | ||
| Q3 25 | 20.7% | 11.7% | ||
| Q2 25 | 16.2% | 12.6% | ||
| Q1 25 | 19.8% | 10.9% | ||
| Q4 24 | 14.8% | 16.3% | ||
| Q3 24 | 17.4% | 14.3% | ||
| Q2 24 | 12.6% | 12.4% |
净利率BSXRVTY
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 12.7% | ||
| Q3 25 | 14.9% | 6.7% | ||
| Q2 25 | 15.7% | 7.5% | ||
| Q1 25 | 14.4% | 6.4% | ||
| Q4 24 | 12.3% | 13.0% | ||
| Q3 24 | 11.1% | 13.8% | ||
| Q2 24 | 7.8% | 8.0% |
每股收益（稀释后）BSXRVTY
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $0.86 | ||
| Q3 25 | $0.51 | $0.40 | ||
| Q2 25 | $0.53 | $0.46 | ||
| Q1 25 | $0.45 | $0.35 | ||
| Q4 24 | $0.38 | $0.77 | ||
| Q3 24 | $0.32 | $0.77 | ||
| Q2 24 | $0.22 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | — | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $919.9M | ||
| Q3 25 | $1.3B | $931.4M | ||
| Q2 25 | $534.0M | $991.8M | ||
| Q1 25 | $725.0M | $1.1B | ||
| Q4 24 | $414.0M | $1.2B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.9B | $2.0B |
总债务BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | — | ||
| Q3 25 | $11.1B | — | ||
| Q2 25 | $11.1B | — | ||
| Q1 25 | $10.5B | — | ||
| Q4 24 | $9.0B | — | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $9.0B | — |
股东权益BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $7.3B | ||
| Q3 25 | $23.4B | $7.4B | ||
| Q2 25 | $22.4B | $7.6B | ||
| Q1 25 | $22.2B | $7.6B | ||
| Q4 24 | $21.8B | $7.7B | ||
| Q3 24 | $20.7B | $7.9B | ||
| Q2 24 | $20.4B | $7.9B |
总资产BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $12.2B | ||
| Q3 25 | $42.7B | $12.1B | ||
| Q2 25 | $41.6B | $12.4B | ||
| Q1 25 | $40.1B | $12.4B | ||
| Q4 24 | $39.4B | $12.4B | ||
| Q3 24 | $38.1B | $12.8B | ||
| Q2 24 | $37.1B | $13.4B |
负债/权益比BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $182.0M | ||
| Q3 25 | $1.3B | $138.5M | ||
| Q2 25 | $1.3B | $134.3M | ||
| Q1 25 | $541.0M | $128.2M | ||
| Q4 24 | $1.5B | $174.2M | ||
| Q3 24 | $1.0B | $147.9M | ||
| Q2 24 | $813.0M | $158.6M |
自由现金流BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $161.8M | ||
| Q3 25 | $1.2B | $120.0M | ||
| Q2 25 | $1.1B | $115.5M | ||
| Q1 25 | $354.0M | $112.2M | ||
| Q4 24 | $1.2B | $149.8M | ||
| Q3 24 | $823.0M | $125.6M | ||
| Q2 24 | $658.0M | $136.6M |
自由现金流率BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | 21.0% | ||
| Q3 25 | 22.9% | 17.2% | ||
| Q2 25 | 22.3% | 16.0% | ||
| Q1 25 | 7.6% | 16.9% | ||
| Q4 24 | 25.8% | 20.5% | ||
| Q3 24 | 19.6% | 18.4% | ||
| Q2 24 | 16.0% | 19.7% |
资本支出强度BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 2.6% | ||
| Q3 25 | 3.6% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 4.0% | 2.4% | ||
| Q4 24 | 6.1% | 3.4% | ||
| Q3 24 | 4.3% | 3.3% | ||
| Q2 24 | 3.8% | 3.2% |
现金转化率BSXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 1.85× | ||
| Q3 25 | 1.78× | 2.97× | ||
| Q2 25 | 1.62× | 2.49× | ||
| Q1 25 | 0.81× | 3.03× | ||
| Q4 24 | 2.59× | 1.84× | ||
| Q3 24 | 2.14× | 1.57× | ||
| Q2 24 | 2.52× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
